GFS Advisors LLC Makes New $1.45 Million Investment in Bristol Myers Squibb Company $BMY

GFS Advisors LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 26,810 shares of the biopharmaceutical company’s stock, valued at approximately $1,446,000.

A number of other large investors have also added to or reduced their stakes in BMY. Physician Wealth Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $32,000. Garner Asset Management Corp bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $35,000. Finally, Beacon Financial Strategies CORP bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $38,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 1.5%

Shares of Bristol Myers Squibb stock opened at $56.43 on Wednesday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market capitalization of $115.23 billion, a PE ratio of 15.85, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a 50-day simple moving average of $57.98 and a two-hundred day simple moving average of $56.73.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the previous year, the company earned $1.80 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts anticipate that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on BMY shares. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays began coverage on shares of Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Royal Bank Of Canada assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Finally, HSBC lifted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $61.31.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.